{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:33:43Z","timestamp":1789832023244,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021021","name":"Kobe City Medical Center General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtocrr.2023.100608","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T22:30:56Z","timestamp":1700346656000},"page":"100608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study"],"prefix":"10.1016","volume":"4","author":[{"given":"Yuki","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Amimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotoko","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2023.100608_bib1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtocrr.2023.100608_bib2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100608_bib3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2023.100608_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2023.100608_bib6","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1158\/1078-0432.CCR-22-0404","article-title":"Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade","volume":"28","author":"Johannet","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2023.100608_bib7","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2023.100608_bib8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jtho.2016.05.028","article-title":"Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC","volume":"11","author":"Arriola","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtocrr.2023.100608_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.20269","article-title":"Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2014.10.040","article-title":"Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies","volume":"348","author":"Raspotnig","year":"2015","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jtocrr.2023.100608_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib13","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jtocrr.2023.100608_bib14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jtocrr.2023.100608_bib15","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jtocrr.2023.100608_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41416-018-0125-7","article-title":"Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies","volume":"119","author":"Vialatte de Pemille","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2023.100608_bib17","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jtho.2019.05.042","article-title":"Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes","volume":"14","author":"Iams","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtocrr.2023.100608_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer--what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2023.100608_bib21","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"Dechelotte","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jtocrr.2023.100608_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2023.100608_bib23","doi-asserted-by":"crossref","first-page":"e4115","DOI":"10.1210\/clinem\/dgac467","article-title":"Elevated TSH level, TgAb, and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade","volume":"107","author":"Kobayashi","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtocrr.2023.100608_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clim.2018.12.007","article-title":"A\u00a0large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values","volume":"199","author":"Seluk","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib25","doi-asserted-by":"crossref","first-page":"fcab220","DOI":"10.1093\/braincomms\/fcab220","article-title":"Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae","volume":"3","author":"Pla\u00e7ais","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.jtocrr.2023.100608_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/neuonc\/nou126","article-title":"A\u00a0prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes","volume":"17","author":"de Jongste","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117103","article-title":"Paraneoplastic neurological syndromes with onconeural antibodies: a single center retrospective study","volume":"418","author":"Oliveira","year":"2020","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jtocrr.2023.100608_bib28","first-page":"2284","article-title":"Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results","volume":"264","author":"Abboud","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1017\/cjn.2018.74","article-title":"The positive predictive value of onconeural antibody testing: a retrospective review","volume":"45","author":"Budhram","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jtocrr.2023.100608_bib30","first-page":"26","article-title":"Epidemiology of paraneoplastic neurological syndromes: a population-based study","volume":"267","author":"Vogrig","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fimmu.2020.01482","article-title":"The diagnostic value of onconeural antibodies depends on how they are tested","volume":"11","author":"Ruiz-Garcia","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/WCO.0b013e328359da15","article-title":"Paraneoplastic neurological syndromes","volume":"25","author":"Graus","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jtocrr.2023.100608_bib33","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:32Z","timestamp":1762987172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364323001510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2666364323001510"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100608","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100608"}}